Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor by Ming Chu et al.
Chu et al. BMC Complementary and Alternative Medicine 2014, 14:89
http://www.biomedcentral.com/1472-6882/14/89RESEARCH ARTICLE Open AccessRole of berberine in anti-bacterial as a high-affinity
LPS antagonist binding to TLR4/MD-2 receptor
Ming Chu1*†, Ran Ding2†, Zheng-yun Chu2, Ming-bo Zhang2, Xiao-yan Liu1, Shao-hua Xie1, Yan-jun Zhai2
and Yue-dan Wang1*Abstract
Background: Berberine is an isoquinoline alkaloid mainly extracted from Rhizoma Coptidis and has been shown to
possess a potent inhibitory activity against bacterial. However, the role of berberine in anti-bacterial action has not
been extensively studied.
Methods: The animal model was established to investigate the effects of berberine on bacterial and LPS infection.
Docking analysis, Molecular dynamics simulations and Real-time RT-PCR analysis was adopted to investigate the
molecular mechanism.
Results: Treatment with 40 mg/kg berberine significantly increased the survival rate of mice challenged with
Salmonella typhimurium (LT2), but berberine show no effects in bacteriostasis. Further study indicated that
treatment with 0.20 g/kg berberine markedly increased the survival rate of mice challenged with 2 EU/ml bacterial
endotoxin (LPS) and postpone the death time of the dead mice. Moreover, pretreatment with 0.05 g/kg berberine
significantly lower the increasing temperature of rabbits challenged with LPS. The studies of molecular mechanism
demonstrated that Berberine was able to bind to the TLR4/MD-2 receptor, and presented higher affinity in
comparison with LPS. Furthermore, berberine could significantly suppressed the increasing expression of NF-κB, IL-6,
TNFα, and IFNβ in the RAW264.7 challenged with LPS.
Conclusion: Berberine can act as a LPS antagonist and block the LPS/TLR4 signaling from the sourse, resulting in
the anti-bacterial action.Background
Berberine is an isoquinoline alkaloid extracted from var-
iety species of plants such as Rhizoma Coptidis [1]. It
has been widely used for treatment of skin inflammation,
diabetes, liver disease [2-4]. More importantly, berberine
has been used in the treatment of enteritis [5,6] for
thousands of years in China, and presents the advantages
of shorter treatment course, faster currative effect, little
side effect, and milder tolerance. However, the role of
berberine in antibacterial action has not been extensively
studied. Since the process of bacterial infection and the
pathogenic mechanisms of bacterial are complicated,
it is hard to define the role of berberine in anti-bacterial
action without an in-depth study. Enteritis is most* Correspondence: famous@bjmu.edu.cn; wangyuedan@bjmu.edu.cn
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reproduction in any medium, provided the orcommonly caused by the ingestion of substances con-
taminated with pathogenic microorganisms, such as
Salmonella and Escherichia [7]. The symtoms of en-
teritis include abdominal pain, cramping, dehydration,
diarrhea and fever, which are mainly caused by the
bacterial endotoxin infection.
Endotoxin is considered to be a toxin kept “within”
the bacterial cell and to be released only after destruc-
tion of the bacterial cell wall. Nowadays, endotoxin is
used synonymously with the term LPS, which is a major
constituent of the outer cell membrane of Gram-negative
bacteria [8,9]. The key effects of LPS on vertebrates are
mediated by their interaction with specific receptors on
immune cells such as monocytes, macrophages, dendric
cells, and others. LPS consists of a hydrophobic anchor,
known as lipid A, a repeating O-antigen polysaccharide,
and an inner core oligosaccharide [10,11]. Many of the im-
mune activating abilities of LPS can be attributed to the
lipid A unit, which binds to the toll-like receptor 4. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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by rapidly triggering pro-inflammatory processes [12-15].
TLR4 alone does not directly bind LPS and requires
its coreceptor myeloid differentiation protein (MD-2)
which is associated with the extracellular domain of
TLR4 and is indispensable for LPS recognition since
MD-2 has a unique hydrophobic cavity which can dir-
ectly bind the lipid A unit [16,17]. The combination
between LPS and TLR4/MD-2 receptor complex can
cause intense innate immune response [18-20]. After
binding LPS, TLR4 undergoes oligomerization and re-
cruits its downstream adaptors via interactions with
the TIR (Toll-interleukin-1 receptor) domains. MyD88
(myeloid differentiation primaryresponse gene 88) is
one of the five TIR domain-containing adaptor proteins.
The TLR4 signaling has been divided into MyD88-
dependent and TRIF-dependent path-way. MyD88 acti-
vates the downstream transcription factors AP-1, IRF-5
and NF-κB. These transcription factors induce expression
of proinflammatory cytokine genes, and thus a series
of proinflammatory cytokines (TNF-α, IFN-γ, IL-1, IL-6)
are produced through the MyD88-dependent pathway
[13,21,22]. Currently, LPS is the most important factor
in induction of IL-1 and TNF [23]. These cytokines can
regulate the immune responses via the activation of various
transcription factors within the fever-controlling region of
the hypothalamus to increase the body temperature [24].
Meanwhile, inflammatory reactions induced by LPS can
also cause diarrhea [25]. Furthermore, according to the re-
cent evidences, TLR4-mediated elevations in the expression
of these cytokines in astrocytes in the central nervous sys-
tem (CNS) and glia cells can initiate and propagate several
debilitating disease states such as sepsis and chronic pain
[26-29]. One study demonstrated that berberine inhibits
LPS-stimulated myocardial TNF-alpha production, impairs
calcium cycling, and improves LPS-induced contractile dys-
function in intact heart within cardiomyocytes exposed to
LPS adopted [30]. Another study which adopted LPS-
stimulated macrophages demonstrated that berberine could
inhibit COX-II activity [31]. Other studies have indicated
that Berberine could attenuate tissue injury of the lungs
and intestine in mice challenged with LPS and could sup-
press the activation of NF-κB [32-35]. The above men-
tioned studies seem to indicate that berberine may block
LPS signaling and have some preventitive effects on LPS-
induced injury. However, previous research did not clearly
identify the stage at which berberine blocks the LPS inflam-
matory signal.
The crystal structure of human TLR4/MD-2/Ra-LPS
complex [36] has been reported and may interact with
berberine since it has a large hydrophobic surface, which
is likely to compete with LPS in binding to its specific
TLR4/MD-2 receptor, thus blocking the LPS/TLR4 sig-
naling. Based on the previous in vitro and animal work,and on our hypothesis that berberine may block the LPS
signaling by binding to the TLR4/MD-2 receptor, berber-
ine may present alleviative effects on LPS-induced disease
states. In the present study, we first confirmed the anti-
bacterial effect. Afterward, we investigated the therapeutic
effects of berberine on LPS-induced diseases, thereby pro-
viding the evidence supporting the need for the study of
anti-endotoxin mechanism. Furthermore, we explored the
molecular mechanisms of the action of berberine.
Methods
Materials
Berberine was provided by Liaoning University of Traditional
Chinese Medicine. Endotoxin was provided by National
Institutes for Food and Drug Control. (titer: 9000 EU/amp).
Bacterial strains
Wild type S.typhimurium LT2 was purchased from ATCC
(Catalog number: 15277). LT2 was grown in Luria-Bertani
(LB) medium at 37°C with shaking at 200 rpm. When ap-
propriate, the medium was supplemented with 10 μg of
tetracycline per ml medium or 10 μg of chloramphenicol.
Cell culture and treatment
Murine macrophage-like cells (RAW264.7) were pur-
chased from ATCC and cultured in Dulbecco’s modified
Eagle’s medium (Mediatech Inc., Herndon, VA, USA)
supplemented with 100 μg/ml of penicillin/streptomycin
and 10% heat-inactivated fetal bovine serum (Gibco, FBS),
in a humidified atmosphere of 5% CO2 at 37°C, until
reaching 80% confluency. The medium was changed
every 3 days. These cells were divided into four treat-
ment groups.
Animals and experimental procedures
Balb/c mice(4-6 weeks, weighing 21-23 g)and albino
rabbits(weighing 1.5-2.5 kg) were provided by animals’
raising house of Shenyang Medical College (Certificate
of Conformity: Liao [2010] No. 022). The experimental
animals were housed separately at room temperature
(20 ± 2)°C, humidity 55%-60%. They were provided a
standard laboratory diet and water ad libitum. Before
the experiments, we measured the body temperature
of the rabbits twice a day for three consecutive days.
The rabbits which temperature range from 38.6°C to
39.5°C, and which temperature fluctuation range less
than 0.3°C were selected. All of the experimental pro-
cedures were carried out in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals.
The animal experiments were approved by the Institutional
Animal Care and Use Committee of the Peking University.
The establishment of LT2-infected Balb/c mice model—
All the Balb/C mice challenged via the oral administration
with 7.6 × 105 CFU LT2 by blunt-tipped gauge needle were
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was inoculated orally with 0.5 ml LB broth in the presence
of berberine with different final concentrations (10, 20, 30,
40 mg/kg) for 7 consecutive day. While the mice in non-
treatment group inoculated orally with 0.5 ml LB broth
for consecutive 7 days was set as control. The survival of
mice in each group was assessed once a day for 8 consecu-
tive days.
The establishment of LPS-treated Balb/c mice model—
Each Balb/c mouse was injected intraperitoneally with
2EU/ml bacterial endotoxin(0.5 ml for each mouse). The
mice in berberine group were administered intragas-
trically with berberine solution at the dose of 0.20,
0.16 or 0.13 g/kg, in comparison with the non-treatment
mice which were administered intragastrically with distilled
water (0.01 ml/g). The survival of mice in each group was
assessed once an hour throughout the experiment.
The establishment of LPS-treated pyretic rabbits model—
Before the oral administration, the rectal temperature was
measured once an hour for 2 hours, and the average value
was set as the basal body temperature. The rabbits in ber-
berine group were administered intragastrically with ber-
berine solution at the doses of 0.06, 0.05 or 0.04 g/kg, in
comparision with the non-treament rabbits. One hour after
the administration, the rabbits were injected with 0.8 EU/
kg bacterial endotoxin through their ear vein. Lastly, the
body temperature was measured once an hour for five con-
secutive hour and the changes in body temperature (the
difference between the body temperature and basal body
temperature pyrogenic Δ T °C) were calculated.
Docking studies with autodock 4.2
The crystal structure of human MD-2 complexed with
lipid IVa (2E59. pdb) [37] was used for docking studies
with Autodock v4.2. The protein was processed by re-
moving the native ligand and addition of polar hydrogen
atom and Kollman united-atom partial charges. The ber-
berine was prepared by assigning Gasteiger–Marsilli
atomic charge and defining active torsion groups. Grid
maps were calculated with 40 × 86 × 54 points spacing
by 0.375 Å, centered at point (0.445, 23.87, 13.078) using
Autogrid4. The docking studies were carried out with
flexible ligand using Lamarckian Genetic Algorithm with
the following parameters: translation step (2 Å), quater-
nion step (50°), torsional step (50°), torsinal degree of
freedom (2). All other parameters were set to their de-
fault values. The protein and ligand berberine were fur-
ther prepared with AutodockTools [38]. The analysis of
the docking was performed with AutoDockTools, and
PyMOL software [39].
Molecular dynamics simulations
Molecular dynamics (MD) simulations were carried out
with Gromacs v4.5 program [40,41]. The structure ofprotein was taken from the Protein Data Bank (2E59.
pdb). Gromos96 (53a) force field was used for the pro-
tein, and the parameters for the berberine are generated
with PRODRG web server [42,43]. The protein was sol-
vated with a rectangular water box extending 10 Å from
the protein. Single Point Charge (SPC) model was used
for the waters. Four berberine moleculars were randomly
placed around the protein within 2 Å. Two Cl− ions
were added to neutralize the total charge of system.
In preparation for MD, the system was first subjected
to 1000 steps of steepest descent minimization. Then
the system was heated to the 298 K with the protein par-
tially constrained. Finally 85 ns MD simulation for
equilibration and production was carried out for the sys-
tem with 3D periodic boundary in NPT ensemble im-
posed. Weak coupling methods [44] were applied with
coupling constants of 0.1 ps and 0.5 ps respectively to
maintain the systems at 298 K and 1 Bar. Bonds involv-
ing hydrogen were constained with LINCS algorithm for
protein and SETTLE algorithm for water [45,46], thus
permitted using a integrate step of 2 fs. Electrostatic in-
teractions were treated by utilizing Particle Mesh Ewald
(PME) method [47,48] beyond the cutoff at 10 Å. Van
der Waals interactions were cut off at distance of 14 Å.
Neighbor lists were used with a list cutoff of 10 Å and
update frequency of every 10 steps. Snapshots of trajec-
tories were saved every 10 picoseconds for analysis.
Real-time RT-PCR analysis of NF-κB, IL-6, TNFα, and IFNβ
mRNA expression
Total RNA was recovered from RAW264.7 cells using
the Trizol reagent (Invitrogen) and Dnase treated using
Turbo Dnase® (Ambion). RNA was reverse transcribed
using the Superscript™ first-strand cDNA synthesis kit
(Invitrogen). Primer sequences for mouse NF-κB were
5′-CAG CCA GGA TTG AGG ATA TGA G-3′ and 5′-
TTC GGA CAA CAG AAG TCA GGA G-3′; for IL-6
were 5′-AAC GAT GAT GCA CTT GCA GA-3′ and
5′-GAG CAT TGG AAA TTG GGG TA-3′; for TNFα
were 5′-TCC CCA AAG GGA TGA GAA GTT C-3′
and 5′-TCA TAC CAG GGT TTG AGC TCA G-3′; for
IFNβ were 5′-CCA CAG CCC TCT CCA TCA AC-3′
and 5′-CTA CCA CCA GGC TCG TCT CT-3′; for β-
actin were 5′-ATG GGT CAG AAG GAC TCC TAC G-
3′ and 5′-AGT GGT ACG ACC AGA GGC ATA C-3′,
for the sense and antisense primers, repectively. Thermal
cycling conditions for the PCR reactions were 94°C for
5 min followed by 40 cycles of 94°C for 45 s, 61°C for
30 s, and 72°C for 30 s. Polymerase reaction products
amplified by these primers were cloned into pGEMT vec-
tor (Promega) and sequenced for verification. Real-time
reactions were carried out on a real-time machine (Biorad)
using the IQ™ SYBR® Green Supermix kit (Biorad). The
abundance of each gene product was calculated by
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same reaction with their respective plasmids. The NF-κB,
IL-6, TNFα, and IFNβ values for each sample were nor-
malized to β-actin.
Statistical methods
Statistic analyses were performed by using SPSS 13.0
software. The data are expressed as mean ± SD. Student’s
T test was used in the data statistics. Values of P < 0.05
were considered significant.
Results
Anti-bacterial effects of berberine
As described previously, berberine has been widely used
for treatment of bacterial infection disease, and presents
antibacterial acitivity. However, the role of berberine in
antibacterial action has not been extensively studied.
Therefore, we first investigated its effect on LT2 infected
mice. Preliminary test have presented the LD50 of
Salmonella typhimurium LT2 gavage at 7.5 × 105 CFU
per mouse and each 4-6-week old Balb/c mouse was chal-
lenged with LD50 of LT2. The results show that 50% of
the mice without berberine treatment died by the end of
the 8th day following infection. By contrast, after treated
with 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg
berberine, 60, 60, 70 and 90 percent of the infected
mice survived to the 8th day, respectively (Figure 1).
Meanwhile, the infected mice without berberine treat-
ment lost 18.96 ± 2.58 percent of their body weight,
whereas those in the berberine treatment group main-
tained or increased their weight. Meanwhile, we also
proved that berberine have no effects in bacteriostasis
(data not shown).Figure 1 Therapeutic effect of berberine on LT2-challenged
Balb/c mice. n = 10 in each group. Each mouse was challenged
with 7.6 × 105 CFU LT2. Mice in berberine group was inoculated
orally with 0.5 ml LB broth in the presence of berberine with
different final concentrations (10, 20, 30, 40 mg/kg) for consecutive
7 days, whereas mice in control group was inoculated orally with
0.5 ml LB for consecutive 7 days. The survival was assessed every
24 h throughout the experiment.Effects of berberine on the survival from LPS induced
death of BalB/C mouse
It is known that endotoxin(LPS) plays an important role
in the bacterial infection process and berberine was ex-
pected to present some anti-endotoxin effects. There-
fore, LPS-challenged Balb/c mice model was established
to investigate whether berberine could reduce the mor-
tality rate of mice challenged with LPS. Preliminary test
indicated that the mice injected intraperitoneally with
2 EU/ml endotoxin solution (0.5 ml of each) reached
a lethal rate of 80% and every 4-6-week old Balb/c mouse
were injected with 2 EU/ml bacterial endotoxin(0.5 ml for
each mouse). The results show that 80% of the mice with-
out berberine treatment died, and the average death time
is 6.27 ± 4.72 hours. By contrast, After treated with
0.20 g/kg, 0.16 g/kg and 0.13 g/kg berberine, 60, 50,
and 50 percent of the infected mice survived respect-
ively, and the average death time of each group were
16.17 ± 7.77, 14.89 ± 5.74 and 12.96 ± 6.51 hours, which
was significantly better than that of mice only exposed to
LPS (P < 0.05) (Figure 2).
Effects of berberine on the LPS induced fever of pyretic
rabbit
Based on the hypotheis that berberine may block the
LPS signaling, berberine is expected to present the abil-
ity to relieve fever caused by LPS. In the present study,
we investigated the antipyretic effect of berberine on
LPS-challenged rabbits. Each rabbit was injected with
0.8 EU/kg LPS. The changes in body temperature of the
rabbits treated with 0.06, 0.05 or 0.04 g/kg berberine are
significantly lower than those of the non-treatment
group, and the 0.05 g/kg treatment group presented the
most siginificant effects. (P < 0.05) (Figure 3).
Role of berberine in the combination between LPS and its
receptor molecules
As described above, berberine exhibits significant anti-
endotoxin effects. To gain insights into the possible anti-
bacterial mechanism, we further investigated the role of
berberine LPS/TLR4 signaling pathway.
The LPS triggers signal transduction pathway leading
to inflammatory reaction by binding to TLR4/MD-2 re-
ceptor via hydrophobic interaction. Being characteris-
tized by its hydrophobic surface, berberine was expected
to exibit an antibacterial activity by acting as an LPS
antagonist. To prove this assumption, we carried out
docking calculation to explore the interaction between
berberine and MD-2. Our docking study demonstrated
that berberine could bind to free MD-2 with binding free
energy of -7.70 kcal/mol. The binding cavity of MD-2 is
large enough that it would still have sufficient empty space
even though a molecule of berberine had bound to it. To
investigate whether the MD-2 could hold more than one
Figure 2 Therapeutic effect of berberine on LPS-challenged Balb/c mice. n = 10 in each group. Each mouse was injected with 2 EU/ml
bacterial endotoxin (0.5 ml for each). The LPS-challenged mice was administered intragastrically with distilled water (0.01 ml/g) or berberine at
doses of 0.20, 0.16 or 0.13 g/kg. The survival was assessed once an hour throughout the experiment. The average death time of each group was
calculated within Mean ± SD adopted. P < 0.05 vs control.
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ally. As a result, the cavity of MD-2 could hold two
more berberine molecules with the binding energies
of -7.33 and -6.75 kcal/mol respectively. Therefore, a
MD-2 receptor with an open cavity could accept at least
three berberine molecules. And the molecular planes,
were arrangred nearly in parallel (Figure 4A).
Since proteins are usually solvated by water under
physiological conditions, it is essential to investigate
whether berberine could bind to MD-2 under the influ-
ence of water solvent. Therefore, we carried out a MD
simulation of a system with four molecules of berberine
randomly distributed around MD-2. The initial con-
struction was subtracted from the crystal structure
(2E59.pdb) with an open cavity. And we found that the
presence of water solvent squeezed MD-2 so stronglyFigure 3 Changes in body temperature of the LPS-challenged
rabbits. n = 6 in each group. The rabbits were administered with
berberine at the doses of 0.06, 0.05 or 0.04 g/kg, in compartion with
the non-treament rabbits. Each rabbit was injected with 0.8 EU/kg
LPS. The changes in body temperature was assessed every 24 h
throughout the experiment. Mean ± SD. **P < 0.01, *P < 0.05
vs control.that the hydrophobic cavity of the MD-2 was collapsed
through MD simulation. However, one of the four mole-
cules of berberine was still observed to enter the cavity of
MD-2 after 85 ns of MD simulation (Figure 4B). Mean-
while, another molecule of berberine approached to the
enrance to the cavity.
Role of berberine in LPS induced expression of NF-κB and
cytokines
Upon challenge with LPS, cells form a broad spectrum
of immune mediators such as cytokines which can lead
to LPS-related disease states. To confirm that berberine
could block the LPS signaling, we employed real-time
analysis in the present study. we proved that berberine
could significantly inhibit the increasing expression of
NF-κB, IL-6, TNFα and IFNβ stimulated by LPS in the
LPS-challenged RAW264.7, in comparison with the nega-
tive control (Figure 5).
Discussion
Berberine has been used in the treatment of enteritis
[5,6] for thousands of years in China, and presents the
advantages of shorter treatment course, faster currative ef-
fect, little side effect and milder tolerance. However, the
mechanism of berberine in anti-bacterial is still unclear.
In this study, we showed that berberine had no effect
on bacteriostasis. As known, LPS plays an important role
in bacterial infection. Therefore, we assumed that the
anti-bacterial effects of berberine might be related to its
inhibitory action on LPS infection. As we expected, The
results indicated that berberine could reduce the lethal
rate of mice infected by LPS, and extend the survival time.
Subsequently, we demonstrated that berberine could sig-
nificantly relieve fever of rabbits induced by LPS. Based
on these, we believe that there must exsits some definite
link between berberine and LPS signaling.
Figure 4 Role of berberine in the combination between LPS and its receptor molecules. A. The docking analysis of berberine and MD-2.
The binding free energies of the three berberine molecules was -7.70 kcal/mol, -7.33 and -6.75 kcal/mol respectively. B. A MD simulation of a
system with four molecules of berberine randomly distributed around the MD-2 solvated by water.
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can reduce the mRNA expression of NF-κB, IL-6, TNFα
and IFNβ in LPS-challenged RAW264.7. Other studies
have indicated that LPS significantly induced enterocyte
apoptosis, increased TLR4 mRNA expression, MIP-2
production, I-κBα phosphorylation, and myeloperoxidase
content in the ileum and pretreatment of berberine alle-
viated all the alterations [14]. Beside these, another study
showed that berberine can suppress the activation of
TLR4 and NF-κB in the ileum of mice [15]. Those men-
tioned studies seem to verify that berberine can block
the LPS/TLR4 signaling pathway. But former studies
have not revealed how berberine block the signaling.
Since the binding of Lipid A and the hydrophobic cav-
ity of MD-2 play an key role in LPS recognition, and aFigure 5 The Realtime PCR analysis for NF-κB (A), IL-6 (B), TNFα and I
treatment as described previously. LPS group was recognized as a control
showed the expression of NF-κB, IL-6, TNFα and IFNβ, respectively.Each gro
berberine, respectively.berberine molecule has a large hydrophobic surface, we
hypothesized that berberine would be likely to compete
to bind TLR4/MD-2, thereby blocking the signaling. We
first adopt docking calculation to investigate whether the
berberine molecules can bind to the MD2. The results
indicated that berberine could bind to free MD-2 with
binding free energy of -7.70 kcal/mol. The binding cavity
of MD-2 is large enough that it would still have suffi-
cient empty space although a molecule of berberine have
already bound to it. Afterward, the other berberine mol-
ecules was docked continually into MD-2. As a result, the
cavity of MD-2 could hold two more berberine molecules
with the binding energies of -7.33 and -6.75 kcal/mol
respectively. Therefore, a MD-2 receptor with an open
cavity could accept at least three berberine molecules.FNβ mRNA expression in RAW264.7. It was conducted 1 h after
and data was expressed as the ratio to LPS group. A, B, C and D
up was treated with NS(control), berberine, LPS and LPS mixed with
Figure 6 The role of berberine in TLR4/MD-2 signaling. The recognition of LPS is facilitated by LBP and CD14, and is mediated by TLR4/MD-2
receptor complex. Upon the recognition, LPS/TLR4 signaling can be separated into MyD88-dependent and MyD88- independent pathways, which
mediate the activation of proinflammatory cytokine and Type I interferon genes.
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to MD-2 under the influence of water solvent, a MD
simulation of a system with four molecules of berberine
randomly distributed around MD-2 was carried out. The
presence of water solvent squeezed MD-2 so strongly
that the hydrophobic cavity of the MD-2 was col-
lapsed. However, one of the four molecules of berberine
was still observed to enter the cavity of MD-2 after 85 ns
of MD simulation. Meanwhile, another molecule of ber-
berine approached to the enrance to the cavity. It can be
expected that this molecule might also enter the pocket if
a longer simulation was performed.
As it was mentioned above, the compression of water
solvent rendered the cavity of MD-2 narrow down and the
lipid A of LPS is too large to get into the narrow cavity
directly. Therefore, some transitional proteins are neces-
sary. The induction of inflammatory responses by LPS is
achieved by the coordinated and sequential action of fourprincipal endotoxin-binding proteins: lipopolysaccharide-
binding protein (LBP: a soluble shuttle protein which
directly binds to LPS and facilitates the association between
LPS and CD14), CD14 (a glycosylphosphatidylinositol-
anchored protein which facilitates the transfer of LPS to
the TLR4/MD-2 heterodimers and modulates LPS recog-
nition), MD-2 and TLR4 [49-53]. By contrast, berberine
do not generally require the canonical LPS presentation
sequence to bind the receptor. As the size of mol-
ecule is small enough, berberine molecules can directly
bind to MD-2 with the hydrophobic surface. From
this, we can easily speculate that the more berberine
molecules get into the cavity, the smaller chance that
LPS can bind to MD-2, which suggest that berberine
take priority over LPS in binding MD-2, thus inter-
rupting the recognition of LPS. Overall, we provided
a theoretical basis that berberine can act as a receptor
antagonist— it can block the LPS/TLR4 signaling
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immune response induced by LPS.
TLR4 has therefore been recognized as an important
pharmacological target. In addition to being responsible
for fever and diarrhea, the TLR4 activation caused by
endotoxin with subsequent cytokine production can lead
to life-threatening syndromes such as sepsis and septic
shock. Mortality of patients who has suffered from septic
shock is still 40%–60% despite rapid progress in develop-
ing antibiotics and other therapeutic methods in clinical
practice [12]. Some drugs were designed and synthesized
to interrupt LPS from binding to TLR4/MD2 receptor
complex, such as Eritoran, Taxol and some protein drugs.
With the advantage of lower cost, faster currative effect,
and little side effect, berberine, the newly-discovered LPS
antagonist, could be widely utilized as a substitute for ex-
pensive drugs in the treatment of LPS-induced diseases.
Furthermore, in recent years, the phenomenon of the
over prescription ofantibiotics have led to increased bac-
terial resistance to antibiotics. Berberine are expected to
be such a kind of drug which can be widely used in the
clinical treatment of wide range of diseases instead of
antibiotics in order to decrease the over use of antibi-
otics which have led to progression of increased bacterial
antibiotic resistance.. Based on this, it is essential to figure
out the antibacterial mechanism of berberine in order
to provide a theoretical basis for the further applica-
tion of berberine in the treatment of diseases caused
by the infection of bacteria and the endotoxin (LPS)
released by bacteria. Since the process of bacterial in-
fection is complicated, there might exist other pos-
sible antibacterial mechanisms of berberine which we
will further investigate. We believe that further study
on berberine will aid in our ability to design effective
interventions and treatments for bacterial infection
diseases.
Conclusion
Berberine can act as a LPS antagonist and block the
LPS/TLR4 signaling from the sourse, resulting in the
anti-bacterial action.Competing interests
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